Table 1.
Patients characteristics at baseline
| Imaging Part | Therapeutic Part | ||||
|---|---|---|---|---|---|
| N = 20 | N = 8 | ||||
| N (%) | Arm A | Arm B | |||
| N | N | ||||
| Number of Patients | 20 | 3 | 5 | ||
| Sex | |||||
| Men | 10 (50.0%) | 2 | 3 | ||
| Women | 10 (50.0%) | 1 | 2 | ||
| Age at inclusion (years) | |||||
| Mean | 42.1 | 31.0 | 41.4 | ||
| SD | 13.68 | 10.44 | 13.59 | ||
| Median | 43.0 | 26.0 | 43.0 | ||
| Range | 21–67 | 24–43 | 21–57 | ||
| PS (ECOG) | |||||
| 0 | 8 (40.0%) | 1 | 2 | ||
| 1 | 10 (50.0%) | 2 | 2 | ||
| 2 | 2 (10.0%) | 0 | 1 | ||
| Primary tumor sites (at initial diagnosis) | |||||
| Upper limb | 1 (5.0%) | 0 | 1 | ||
| Lower limb | 8 (40.0%) | 2 | 2 | ||
| Trunck wall | 5 (25.0%) | 0 | 2 | ||
| Internal trunck | 4 (20.0%) | 0 | 0 | ||
| Head and neck | 2 (10.0%) | 1 | 0 | ||
| Histological type | |||||
| Missing | 1 | 0 | 1 | ||
| Spindle cell | 14 (73.7%) | 3 | 2 | ||
| Biphasic | 2 (10.5%) | 0 | 1 | ||
| Poorly differentiated | 3 (15.8%) | 0 | 1 | ||
| Histological grade at initial diagnosis | Grade 2 | 7 (35.0%) | 3 | 2 | |
| Grade 3 | 13 (65.0%) | 0 | 3 | ||
| T | T1 | 5 (25.0%) | 0 | 2 | |
| T2 | 14 (70.0%) | 3 | 3 | ||
| TX | 1 (5.0%) | 0 | 0 | ||
| N | N0 | 19 (95.0%) | 3 | 5 | |
| N1 | 1 (5.0%) | 0 | 0 | ||
| M | M0 | 20 (100%) | 3 | 5 | |
| Tumor depth | |||||
| Superficial | 3 (15.0%) | 1 | 2 | ||
| Deep | 17 (85.0%) | 2 | 3 | ||
| Disease status at inclusion | |||||
| Metastatic | 18 (90.0%) | 3 | 4 | ||
| Locally advanced | 1 (5.0%) | 0 | 1 | ||
| Both | 1 (5.0%) | 0 | 0 | ||
| Surgery of the primary tumor | |||||
| Yes | 18 (90%) | 3 | 4 | ||
| No | 2 (10%) | 0 | 1 | ||
| Prior Radiotherapy | |||||
| Yes | 15 (75.0%) | 3 | 3 | ||
| No | 5 (25.0%) | 0 | 2 | ||
| Chemotherapy with Doxorubicin | |||||
| Yes, in monotherapy | 5 (25.0%) | 1 | 2 | ||
| Yes, associated | 15 (75.0%) | 2 | 3 | ||
| Chromosomal translocation site | |||||
| missing | 1 | 0 | 0 | ||
| SSX1 | 11 (57.9%) | 1 | 4 | ||
| SSX2 | 5 (26.3%) | 1 | 0 | ||
| Others | 3 (15.8%) | 1 | 1 | ||